Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11242963 | 0.99 | HCAR3 (0.97) | HCAR3MAPTGAAPRSS1NPC1 | |
| SCHEMBL6044600 | 0.99 | HCAR3 (0.97) | HCAR3MAPTGAAPRSS1NPC1 | |
| SCHEMBL11208444 | 0.99 | HCAR3 (0.97) | HCAR3MAPTGAAPRSS1NPC1 | |
| SCHEMBL6044176 | 0.96 | HCAR3 (1.00) | HCAR3MAPTGAAPRSS1NPC1 | |
| SCHEMBL2688335 | 0.91 | HCAR3 (1.00) | HCAR3MAPTNPC1ALDH1A1PKM | |
| SCHEMBL9192588 | 0.87 | HCAR3 (0.77) | HCAR3MAPTPRSS1NPC1ALDH1A1 | |
| SCHEMBL10524428 | 0.87 | HCAR3 (0.76) | HCAR3MAPTGAAPRSS1NPC1 | |
| SCHEMBL3278681 | 0.86 | HCAR3 (0.78) | HCAR3MAPTPRSS1ALDH1A1 | |
| SCHEMBL11267808 | 0.85 | HCAR3 (0.81) | HCAR3MAPTGAAPRSS1NPC1 | |
| SCHEMBL20066439 | 0.85 | HCAR3 (0.74) | HCAR3MAPTPRSS1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-0685470-B1 | Benzene derivatives and pharmaceutical composition | KUREHA CHEMICAL IND CO LTD (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-0685470-A2 | Benzene derivatives and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885MAPT 3284/4885GAA 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.